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by Jose Jauregui 
 




 Trichomonas vaginalis is an anaerobic, parasitic protozoan, responsible for 
trichomoniasis, the world’s most common, non-viral sexually transmitted infection.  
Lacking many of the defenses present in other organisms to combat oxidative stress, 
Trichomonas vaginalis relies extensively on the thioredoxin system—NADPH, 
thioredoxin reductase, and thioredoxin—as a means to protect against exposure to excess 
oxygen.  Current trichomoniasis treatment relies exclusively on the 5-nitroimidazole 
drugs, but fear of drug-resistant strains and allergic reactions to 5-nitroimidazole 
treatment necessitate the discovery of a new treatment method for trichomoniasis.  
Previous research has shown that auranofin, an FDA-approved drug, was effective at 
inhibiting activity of one of Trichomonas vaginalis’ isoforms of thioredoxin reductase (of 
which the organism has five total).  Our research showed that only two of the isoforms 
were transcribed and expressed at high levels, and that both of these isoforms were 
susceptible to auranofin treatment.  Not only that, these two isoforms were also shown to 
be susceptible to various auranofin analogs, having comparable or lower IC50 values.  
Further tests on these analogs might show that they are actually better treatment  
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candidates if they exhibit less symptoms than auranofin.  Experiments examining how 
mRNA and protein levels were modulated in response to two different concentrations of 
auranofin treatment showed that while some isoforms show increased levels, no one 
isoform experienced any drastic changes.  Together, this data suggests that further studies 
should focus on these two most highly expressed isoforms of thioredoxin reductase
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Chapter 1: Introduction 
 
 
 Trichomoniasis is the most common, non-viral sexually transmitted infection 
(STI) worldwide (Secor et al., 2014).  Globally, there an estimated 248 million new cases 
each year (World Health Organization, 2011).  In the United States, there are an 
estimated 3.7 million infected individuals, with around 1.1 million new infections each 
year, arguably making trichomoniasis the nation’s most prevalent parasitic infection 
(Satterwhite et al., 2013).  Despite this, research concerning the infection and new 
treatment methods haven’t received the same level of priority as those of other STIs 
(Secor et al., 2014).  Trichomoniasis’ status as a neglected infection can be attributed to 
two main reasons: 1) there is a lack in the understanding of the infection’s full impact on 
public health (Secor et al., 2014), and 2) the infection has the highest incidence among 
minority and low-income populations (Van der Pol, 2007). 
Trichomoniasis is indiscriminate in affecting both sexes, although the majority of 
infected individuals are asymptomatic (Satterwhite et al., 2013).  Symptoms typically 
manifest with greater occurrence in women, and can also be more severe (Secor et al., 
2014).  When present in women, symptoms typically manifest as swelling of the vagina, 
cervix, and urethra, vaginal discharge, and what’s known as strawberry cervix—small 
lesions on the genital epithelium (Wølner-Hanssen et al., 1989).  These symptoms are 
typically mild to moderate in severity, however (Swygard, 2004).  More adverse side 
effects of infection may be exhibited, particularly in pregnant women; trichomoniasis 
infection during pregnancy has been linked to amniotic sac rupture and stillborn birth 
12 
(Minkoff et al., 1984), preterm labor (Mann et al., 2010), and newborns with low birth 
weights (Cotch et al., 1997). 
Conversely, the impact trichomoniasis has on men tends to be far less severe.  The 
frequency of symptomatic infections in men is far lower, and most incidents of infection 
are believed to resolve themselves without the need for treatment (Weston and Nicol, 
1963).  In the few men that are symptomatic, the most common symptom is the swelling 
of the urethra, and again, this symptom is typically mild to moderate in severity (Krieger 
et al., 1993).  Of course, being asymptomatic doesn’t negate the dangers of the infection.  
Asymptomatic men are still fully capable of transmitting trichomoniasis, and because 
they show no symptoms, are most likely unaware of the risk they pose to their sexual 
partners. 
Common to both sexes is the dangerous link between trichomoniasis and HIV 
(Allsworth et al., 2009).  Infection has been connected with making afflicted individuals 
more susceptible to other STIs, most notably, HIV; infected persons are both more likely 
to acquire and transmit HIV (Hughes et al., 2012).  Individuals with both trichomoniasis 
and HIV have also been seen to be more resistant to trichomoniasis drug treatment, 
necessitating a longer treatment period (Kissinger et al., 2008).  Because of the 
connection between trichomoniasis and HIV, it has been proposed that a more cost-
effective means of reducing HIV transmission might lie through programs aimed at 
stemming and controlling trichomoniasis infections (Price et al., 2006), since 
trichomoniasis is much cheaper to treat than HIV (Owusu-Edusei et al., 2013). 
Trichomoniasis is caused by infection with the protozoan parasite Trichomonas 
vaginalis (T. vaginalis) (Petrin et al., 1998).  T. vaginalis is microaerophilic, meaning that 
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it requires the presence of some oxygen to survive, but high concentrations of oxygen are 
damaging and toxic (Petrin et al., 1998).  In fact, it has been shown that the organism 
grows most optimally when exposed to concentrations of oxygen around .25µM (Paget 
and Lloyd, 1990).  T. vaginalis is also an amitochondriate, so while lacking mitochondria, 
it possesses unique mitochondria-derived organelles called hydrogensomes that facilitate 
energy production in an environment with limited oxygen levels (Dyall and Johnson, 
2000).  Despite being microaerophilic, the organism is still exposed to oxygen in the 
natural environment, and so must have means of dealing with the resulting oxidative 
stress (Coombs et al., 2004).  Regularly, T. vaginalis is exposed to oxygen concentrations 
of about 60µM, much higher than those needed for optimal growth, and also much more 
harmful (Wagner and Levin, 1978). 
A cell’s extracellular environment is oxygen rich, so secreted proteins will contain 
many stabilizing disulfides (Arnér and Holmgren, 2000).  When looking at the 
intracellular environment, there is much less free oxygen present so proteins will instead 
contain free sulfhydryl groups, reflecting this reducing environment (Gilbert, 1990).  
Many proteins contain -SH groups that serve structural and catalytic roles, and the 
unwanted oxidation of these important groups usually results in altered protein function 
(Holmgren, 1985).  It is because of this that cells maintain a reduced intracellular 
environment.  T. vaginalis, in particular, has hydrogenosomal-specific proteins that are 
deactivated by oxygen (Coombs et al., 2004).  Malfunctioning energy generating 
organelles would be detrimental to the organism.  Cells themselves also readily use thiol-
disulfide exchange reactions in protein pathways to control protein function because of 
how fast and easily reversible they are (Arnér and Holmgren, 2000).  Because excess 
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oxygen has the capacity to hinder energy production in T. vaginalis and disrupt the 
organism’s protein pathways, ways to combat possible oxidative stress are required.  
Many other eukaryotes have molecules such as glutathione, glutaredoxins, and 
catalase to serve as redox buffers and antioxidants to protect against the oxidative stress 
and reactive oxygen species (ROS) that proceed exposure to high levels of oxygen (Ellis 
et al., 1994).  T. vaginalis, however, lacks these protective molecules (Ellis et al., 1994).  
What the organism does possess, that is also found in most other organisms, is the 
thioredoxin system (Holmgren, 1985).  Lacking other conventional means of protection, 
T. vaginalis relies almost exclusively on the thioredoxin system to protect against 
oxidative stress.   
The thioredoxin system consists of NADPH, thioredoxin (Trx), and thioredoxin 
reductase (TrxR) (Arnér and Holmgren, 2000).  NADPH gives an electron to TrxR, 
which is then able to reduce Trx, making it active and capable of reducing downstream 
targets (Figure 1).  Trx is a dithiol-disulfide oxidoreductase, meaning that it specifically 
targets disulfides, reducing them into two free thiol groups (Holmgren, 1995).  When 
looking at proteins specifically, the rate at which Trx targets proteins is much higher than 
glutaredoxin (a member of the very similar glutaredoxin system), which is why in many 
organisms the Trx system is the main way in which reducing conditions are maintained 







 The Trx system, acting through Trx, serves many roles.  As stated above, thiol-
disulfide exchange reactions are used in many signal transduction pathways.  Many 
organisms have thus co-opted Trx and integrated it into various pathways within cells 
that serve crucial functions beyond just relieving oxidative stress (Table 1) (Arnér and 
Holmgren, 2000).  One of the more notable functions of Trx outside of combatting 
oxidative stress is its ability to reduce ribonucleotide reductase, a critical enzyme 
involved in DNA synthesis (Holmgren, 1989).  However, despite being dubbed a 
“moonlighting protein,” the Trx protein in T. vaginalis, a unicellular eukaryotic 
organism, doesn’t possess the many robust functions of Trx found in a more complex, 
multicellular organisms (Jeffery, 1999).  The best characterized Trx is that of E. coli, and 
Figure 1.  General scheme of the enzymatic reactions of the thioredoxin system. 
NADPH transfers an electron to TrxR. TrxR then reduces the disulfide in Trx-(SH)2, 
producing two thiols in Trx-S2.  Once reduced, Trx can exert its oxidoreductase 
activities and reduce other downstream targets such as disulfides in proteins (from 
Arnér and Holmgren, 2000). 
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when the Trxs of other organisms are compared to it, a sequence similarity ranging from 
27-69% is observed (Eklund et al., 1991).  It can be assumed that the different functions 




 Trx, through it’s oxidoreductase activity, plays two main roles: 1) it serves as an 
electron carrier in signal transduction 2) and it protects the inactivation and aggregation 
of cytosolic proteins by reducing intra- or inter-molecular disulfides that arise as a 
consequence of oxidative stress (Arnér and Holmgren, 2000).  Again, because T. 
vaginalis lacks the complexity present in multicellular organisms, it’s the second role of 




Trx—and by extension, the Trx system—that’s of greater importance to the organism.  
Indeed, previous studies have demonstrated that exposure to oxidative stress results in 
increased levels of Trx and TrxR in T. vaginalis, highlighting the Trx system’s 
importance in helping the organism overcome the dangers of oxidative stress (Coombs et 
al., 2004).   
 Although the Trx system is T. vaginalis’ main source of antioxidant activity, the 
system doesn’t act alone, particularly when dealing with reactive oxygen species (ROS) 
(Nakamura et al., 1997).  Within the organism, free oxygen is dealt with directly by 
NADH oxidase and NADPH oxidase (Coombs et al., 2004).  NADH oxidase converts 
free oxygen to water, and NADPH oxidase converts it to hydrogen peroxide.  
Additionally present is superoxide dismutase, whose function of eliminating superoxide 
radicals also results in the production of hydrogen peroxide (Petrin et al., 1998).  While 
water is benign, hydrogen peroxide is a ROS and poses a threat to the cell.  A family of 
peroxidases is found within T. vaginalis that reduces and neutralizes hydrogen peroxide .  
These peroxidases are themselves reduced and activated by Trx, and are thus called 
peroxiredoxins (TrxPs) (Hofmann et al., 2002).  Just like the Trx system, these TrxPs are 
thought to be fairly ubiquitous among eukaryotes, highlighting both their importance and 
that of the Trx system (Hofmann et al., 2002).   
Earlier, the ubiquity of the Trx system was mentioned, and while ubiquitous 
across a wide range of organisms, differences are present.  The majority of differences 
concern TrxR.  Most of the non-mammalian organisms that possess a Trx system, such as 
plants, bacteria, yeast, and T. vaginalis, have multiple isoforms of TrxR (Arnér and 
Holmgren, 2000).  T. vaginalis contains five different isoforms (Figure 2), though the 
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reason for this many is yet to be elucidated (Mentel et al., 2008).  This is in contrast to 
humans, who are known to have just one cytoplasmic TrxR, as well as a TrxR specific to 
mitochondria (Spyrou et al., 1997).  The other main difference between the TrxRs of 
different organisms is that they are divided into two groups (Hirt et al., 2002).  Less 
complex organisms, of which T. vaginalis is included, contain low molecular weight 
TrxRs (~33 kDa); and more complex organisms contain high molecular weight TrxRs 







Concerning trichomoniasis, current treatment relies almost exclusively on the 5-
nitroimidazole drugs metronidazole and tinidazole (Leitsch et al., 2012).  Metronidazole 
is the main treatment method, with tinidazole usually reserved only for metronidazole-
Figure 2.  Amino acid sequence alignment of the five TrxR isoforms of T. vaginalis 
(from Mentel et al., 2008).  Numbers on the left denote the shortened names of the 
isoforms (Table 2).  Grey boxes are highlighting the four amino acids that make up 
the active site. 
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resistant strains (Seña et al., 2014).  The nitroimidazoles are selectively toxic to 
microaerophiles and anaerobes (Leitsch et al., 2010).  This is because the nitroimidazoles 
are actually prodrugs, and must be reduced in order to exert toxicity (Edwards, 1993).  
Reduction can still occur in aerobic organisms, but the abundance of oxygen quickly 
leads to the reoxidation of the drug, a process termed a “futile cycle” (Lloyd and 
Pedersen, 1985).  This is good news for the T. vaginalis’s host, humans, since we are 
aerobic organisms, and so our cells are resistant to the drugs effects.   
One main concern with the use of the nitroimidazoles is resistance. The first 
metronidazole-resistant strains were isolated in 1959, very soon after the drug was first 
introduced (Watt and Jennison, 1960).  What’s unclear, however, is if these strains were 
naturally resistant to the drug or if their resistance arose through selection via drug 
treatment (Secor et al., 2014).  A disparity exists when looking at cases of resistance on a 
global scale. In the U.S., only 5% of cases have exhibited metronidazole resistance 
(Schwebke and Barrientes, 2006).  This is in contrast to 17% of cases in Papua New 
Guinea (Upcroft et al., 2009).  Most metronidazole-resistant strains have been susceptible 
to tinidazole (Sobel et al., 2001), though some have been shown to be resistant to both 
drugs, making cross-resistance a great concern (Goldman et al., 2009).   
Other pressing concerns also exist regarding metronidazole treatment.  It has been 
noted that individuals also infected with HIV are more resistant to standard 
metronidazole treatment (Kissinger et al., 2008).  Additionally, a small percentage of 
people are allergic to nitroimidazoles, although this can usually be circumnavigated 
through the use of incremental dosages (Helms et al., 2008).  Those people that suffer 
severe anaphylaxis upon exposure to the drug should not be treated with nitroimidazoles, 
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however (Asensio Sánchez et al., 2008).  But due to nitroimidazoles being the only drugs 
approved for trichomoniasis treatment in the U.S., these individuals have no other course 
of treatment (Secor et al., 2014).  It is because of this that new methods to treat 
trichomoniasis are needed.  
Auranofin is an FDA-approved gold(I) compound (Debnath et al., 2012).  It has 
been on the market for 30 years to treat severe cases of rheumatoid arthritis (Casini and 
Messori, 2011).  Despite it’s long history of clinical use, however, it’s precise mechanism 
of action is still not fully known (Casini and Messori, 2011).  As such, studies involving 
the drug have mainly helped to elucidate it’s effects, showcasing its antirheumatic and 
antiproliferative functions (Mirabelli et al., 1985).   
Many tests looking at auranofin’s effects have focused on specific proteins, 
leading to TrxR being a proposed target (Angelucci et al., 2009).  It is believed that the 
drug works by targeting the TrxR enzyme’s active site, rendering it unable to reduce Trx, 
shutting down the Trx system (Ortego et al., 2014).  A recent study was conducted 
looking at auranofin’s potential efficacy in treating amoebiasis (Debnath et al., 2012), an 
intestinal disease caused by the organism Entamoeba histolytica (E. histolytica), a 
protozoan parasite very similar to T. vaginalis (World Health Organization, 1998).  E. 
histolytica is also an anaerobe that relies solely upon the Trx system to guard against 
oxidative stress (Arias et al., 2007).  Results showed auranofin’s effectiveness at 
targeting TrxR, killing the organism (Debnath et al., 2012).   
All of this helps to make auranofin a strong candidate to treat trichomoniasis.  
Already having FDA approval means that the drug can easily be repurposed to treat 
trichomoniasis (Ashburn and Thor, 2004), and having been shown to be safe for humans, 
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the development timeline can be expedited, saving money and effort that would have 
otherwise gone to prove auranofin was not a risk (Ashburn and Thor, 2004).   
The main draw of the drug, though, is that it targets TrxR.  Most importantly, 
auranofin has been shown to be most effective against low molecular weight TrxRs, like 
the ones found in T. vaginalis (Tejman-Yarden et al., 2013).  And although the drug does 
effect high molecular weight TrxRs, like the one found in humans, auranofin’s potency 
for these is greatly reduced (Gromer et al., 1998).  This limits the risk of damaging cross-
reactivity between auranofin and our TrxR if auranofin is taken to treat trichomoniasis.   
As stated above, T. vaginalis lacks other conventional means to combat and deal 
with oxidative stress, and so must rely extensively on the Trx system.  By targeting TrxR 
and rendering it unable to reduce Trx, auranofin is depriving the organism of its sole 
means of preventing oxidative damage.  As a microaerophilic organism, this would prove 
catastrophic for T. vaginalis.  What’s more, auranofin has also been reported to target 
TrxPs (Cox et al., 2008).  This would be doubly damaging for the organism, as auranofin 
could potentially strip it of another key enzyme it needs to protect against oxidative 
attack.   
As with any gold drug, there are side effects linked with auranofin usage, 
stemming from the toxicity of the gold compounds (Taylor et al., 2012).  The most 
common are diarrhea (experienced in around 50% of patients) and a rash (experienced in 
around 25% of patients) (Debnath et al., 2012).  By and large, however, the most pressing 
concern surrounding auranofin is its immunosuppressive activity (Kean and Kean, 2008).  
As stated above, it’s used only to treat severe cases of rheumatoid arthritis, in large part 
due to its effect on the immune system.  The silver lining is that, at minimum, auranofin 
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treatment for rheumatoid arthritis lasts 6 months but can go up to 1 year (Debnath et al., 
2012).  Typical trichomoniasis treatment, on the other hand, can either be one-time or 
two weeks-long (Smith, 2016).  As such, gold toxicity would be of much less concern in 
the short-term treatment of trichomoniasis.   
Previous work with auranofin and T. vaginalis focused on isoform 474 (Hopper et 
al., 2016).  Here it was shown that the drug inhibited the activity of TrxR 474 in a 
concentration dependent manner.  What’s more, auranofin was also shown to suppress 
the growth of T. vaginalis, stressing its effect on the organism.  
This study hoped to expand on the findings of Hopper et al. (2016), and had three 
main aims; for the first, activity assays were conducted against the different isoforms of 
TrxR in T. vaginalis using auranofin and various analogs of auranofin to determine if any 
are more effective at targeting the enzyme and would thus make better drug candidates;  
for the second, mRNA levels of the different isoforms of TrxR were examined when cells 
were treated with and without drug to see if the organism might respond to drug exposure 
by upregulating certain isoforms; and for the third, we took the mRNA analysis further, 
so whole-proteome analysis using mass spectrometry was conducted to see how the 




Chapter 2: Materials and Methods 
 
 
Transformation for Cell Culture/Proliferation 
 Our collaborator provided plasmids of all five TrxR protein isoforms in the pET-
15b vector (Novagen).  Transformations into Invitrogen TOP10F’ cells were carried out 
for each of the five isoforms.  Labeled tubes were placed on ice.  To these tubes, 15µL of 
competent cells were added, followed by .5µL of DNA.  This mixture was incubated on 
ice for 20 minutes, and then heatshocked in a 42°C water bath for 30 seconds.  The tubes 
were then placed back on ice and 100µL of lysogeny broth (LB) was added.  Following 
this, the tubes were incubated at 37°C in a 225 rpm shaking incubator for 45 minutes.  
50µL of the mixtures were then plated on LB plates that had 35µL of ampicillin 
(100µg/mL) added to them.  Plates were incubated overnight in 37°C incubator and then 
stored in the fridge at 4°C. 
Miniprep 
 Overnight culture.  Picked three different colonies from each of the plates of the 
five isoforms that were transformed into TOP10F’ cells.  The colonies were placed into 
culture tubes with 2mL of LB and ampicillin (100µg/mL).  The tubes were incubated 
overnight in a 225 rpm shaking incubator at 37°C. 
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 10 minute miniprep.  The 10 Minute Mini Prep Method from Biotechniques was 
used to isolate construct DNA.   
Restriction Double Digest of pET-15b Construct 
 The pET-15b bacterial expression vector was double digested with Nde1 and 
BamH1-HF to make sure that correct versions all five isoforms were present in the 
vector.  The total volume of the digest mixture was 20µL, and included 2µL of NEB 
CutSmart buffer, 0.5µL Nde1, 0.5µL BamH1-HF, 3µL of plasmid DNA, and 14µL of 
autoclaved H2O.  The plasmid DNA was added last.  The samples were incubated 
overnight at 37°C and then run on a 0.8% agarose gel to visualize the five isoforms.  3µL 
of 10x loading dye was added to each sample, and 10µL of this mixture was loaded.  
10µL of a 1,000 base pair ladder was also loaded.   
Transformation and Pilot Induction 
Transformation for protein expression.  Plasmid DNA was added to New 
England Biolabs (NEB) competent cells for protein expression.  Labeled tubes were 
placed on ice.  To these, 20µL of competent cells were added, followed by .5µL of DNA.  
The mixture was incubated on ice for 20 minutes and then heatshocked for 45 minutes at 
42°C.  The tubes were then placed back on ice and 500µL of super optimal broth with 
catabolite repression (SOC) outgrowth media was added.  Following this, the tubes were 
incubated in a 225 rpm shaking incubator at 37°C for 45 minutes.  10mL of LB and 
ampicillin (100µg/mL) was made in a 50mL conical, and to this, 500µL of the incubated 
mixture was added.  The LB mixture was then grown overnight in the 225 rpm shaking 
incubator at 37°C.   
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Pilot induction.  1mL of the overnight culture was added to 9mL of LB and 
ampicillin (100µg/mL) in an 50mL conical.  This culture was placed in a 225 rpm 
shaking incubator at 37°C until the correct optical density (OD) was reached.  The OD 
was measured at 600nm, and the desired reading was to fall between 0.4-0.8, as this 
represented midlog growth phase.  Once the correct OD was reached, 10µL of isopropyl 
β-D-1-thiogalactopyranoside (IPTG) (1mM final concentration) was added to the 10mL 
culture to induce protein expression.  The cultures were grown for 24 hours.  1.5mL 
samples were taken at 4 and 24 hours to determine which time point resulted better 
expression yields.  The samples were spun down in a microfuge at 16,000xg for 1 minute.  
The supernatants were discarded and the pellets stored at -80°C.   
Western Blot Analysis  
 100µL of SDS loading buffer (800µL of 2X SDS gel loading dye and 200µL of 
1M dithiothreitol (DTT)) were added to the pellets obtained from the pilot inductions.  
Mixture was pipetted up and down to resuspend cells.  Once resuspended, tubes were 
placed on a heat block >95°C for 5 minutes.  Tubes were quickly spun down to pellet any 
remaining debris.  20µL of sample was loaded into the wells of a hand-poured SDS-
PAGE gel.  7.5µL of protein ladder was also loaded.  The gel was run in BioRad 1X TGS 
Running buffer at 125V.  The samples were then transferred from the gel to Whattman 
PROTRAN BA 83 Nitrocellulose membrane at 100V for 1 hour and 15 minutes in 
BioRad 1X TG Transfer buffer (+ methanol).  The membrane was incubated overnight in 
25mL of 5% block (2.5g block + 50mL 1X TBS-T).  Following this, the membrane was 
incubated with 20µL of mouse monoclonal anti-His primary antibody (1:500 dilution in 
10 mL of 1% block (2mL of 5% block in 8mL of 1X TBS-T); Santa Cruz Biotechnology) 
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on a shaker at room temperature for 1 hour.  The membrane was then washed 3x for 10 
minutes with 1X TBS-T (50mL 10X TBS + 450mL H2O + 500µL Tween-20) on a shaker 
at room temperature.  After the washes, the membrane was incubated with 2µL of anti-
mouse horse radish peroxidase (HRP)-linked secondary antibody (1:5000 dilution in 
10mL of 1X TBS-T) for 1 hour on a shaker at room temperature.  The membrane was 
washed 3x as mentioned above.  3mL of HRP substrate (Thermo Fisher Scientific 
(Thermo)) was added to the membrane and spread across its surface.  The membrane was 
visualized using a BioRad Molecular Imager ChemiDocTM XRS+.   
Protein Purification  
 Large-scale induction.  Transformations into BL21 (DE3) cells were carried out 
as mentioned above. The only difference is that the transformed cells were added to 
15mL of LB and ampicillin (100µg/mL) to grow up overnight, instead of 10mL.  The 
15mL of overnight culture was added to 250mL of LB and ampicillin (100µg/mL) in a 
500mL Erlenmeyer flask.  This mixture was incubated in a 225 rpm shaking incubator at 
37°C until the correct OD was reached.  250µL of IPTG (1mM final concentration) were 
then added to induce protein expression.  Cultures were incubated for the optimal time 
based off the results from the pilot inductions above.  The contents of the flask were 
transferred to a 250mL bottle that was spun at 5,000xg for 10 minutes in a Sorvall® 
Super T21 at 4°C.  The supernatant was removed and cell pellet was stored at -80°C.   
 Before cells were spun down in the Sorvall, a 1.5mL sample of the culture was 
taken to tests for induction before proceeding to the purification using the Western blot 
protocol mentioned above.   
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 Protein purification under native conditions.  Before starting the purification 
protocol, a 500mL stock of Buffer F (50mM Tris-HCl (pH 8.0), 0.3M NaCl, 10mM β-
mercaptoethanol, 10% glycerol, 10mM imidazole) was made.  The Tris-HCl, NaCl, and 
glycerol were first added to 425mL of H2O, autoclaved, and then the remaining 
components were added.   
 16mL of Lysis buffer (20mL Buffer F + 100µL of the protease inhibitor 
phenylmethylsulfonyl fluoride (PMSF) (0.2mg/mL) + 200µL lysozyme (100mg/mL)) 
was added to the cell pellet from the large-scale induction and the bottle was placed on 
ice.  The mixture was pipetted up and down using a serological pipette until the pellet 
was resuspended.  The contents were then transferred to a 50mL conical.  The conical 
was placed in an ice bucket horizontally, and the ice bucket was placed on a shaker at 
high speed for 30 minutes.  The mixture was then sonicated on ice with 6x 10 second 
bursts, with a 20 second wait between each burst.  Following sonication, the mixture was 
spun at 10,000xg for 20 minutes in a Sorvall at 4°C.  The supernatant (lysate) was 
transferred to a new 50mL conical.   
 4mL of 50% Ni-NTA slurry (1mL/4mL lysate) were added to a 50mL conical and 
spun at 2,500RPM for 2 minutes in a Sorvall at 4°C.  The supernatant was removed and 
an equal amount of Buffer F was added.  The mixture was resuspended and the spin in 
the Sorvall was repeated.  The supernatant was removed and the lysate was added.  The 
conical was left on a nutator in a 4°C fridge overnight so that the 6xHIS-tag on the 
induced protein would properly bind to the Ni-NTA agarose beads.  After incubating, the 
mixture was spun down at 5,000xg for 2 minutes in a Sorvall at 4°C.  The supernatant 
was moved to a new conical.  The beads were then washed 3x by adding 10mL of Buffer 
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F and placing the conical on a nutator in a 4°C fridge for 10 minutes.  In between the 
washes, the mixture was spun down at 5,000xg for 2 minutes in a Sorvall at 4°C, and the 
supernatant was removed.  After the third wash, the Buffer F-Ni-NTA mixture was 
loaded slowly into a column with the bottom outlet capped so as to not create any air 
bubbles.  This was done in a 4°C fridge, which is where the elutions took place.  The 
bottom outlet was then opened and the flow through was used to pack the beads.  Once 
the beads were packed, a step gradient of increasing concentrations of elution buffers was 
used to elute the protein through gravity filtration.  In total, six elution buffers of different 
concentrations of imidazole were used: 50mM, 100mM, 150mM, 200mM, 250mM, and 
300mM.  2mL of each buffer were used to elute protein, except the beads were washed 
twice with the 300mM buffer, so 4mL total were used for the highest concentration 
buffer.  50µL samples of the lysate, washes, and elutions were taken to analyze using 
Coomassie stain.  Samples were all stored at -80°C.   
 Coomassie stain.  50µL of SDS loading buffer were added to the 50µL samples 
collected from the purification above.  An SDS-PAGE gel was loaded and run as stated 
above.  The gel was then removed and enough InstantBlue dye was added to completely 
cover the gel.  The gel and dye were incubated for 1 hour on a shaker at room 
temperature.  The dye was removed and deionized water was used to destain the gel.  
After destaining, the gel was visualized using the BioRad Molecular Imager ChemiDocTM 







 Bradford assay.  To quantitate the concentration of protein eluted from the native 
purifications, a Bradford assay was conducted.  Stock bovine serum albumin (BSA) at a 
concentration of 10mg/mL was diluted 1:10 to a final concentration of 1mg/mL.  This 
was used to make standards of 2µg/mL, 4µg/mL, 6µg/mL, 8µg/mL, and 10µg/mL.  
Enough H2O was added to bring the total volume to 800µL.  A tube with no added BSA 
had 800µL of H2O added to serve as a blank.  To separate tubes, 5µL of eluted protein 
were added, and again, were mixed with enough H2O to bring the total volume to 800µL.  
All of the tubes had 200µL of Bradford Dye Reagent (BioRad) added to them (final 
concentration 1mL), and were incubated for at least 5 minutes but no greater than 1 hour 
at room temperature.  After incubating, the absorbance for the standards and samples was 
measured at 595nM.  Using Excel, the values for the standards were used to generate a 
standard curve.  The equation of the curve was used to determine the concentrations of 
the samples.   
 Coomassie stain for protein quantitation.  To ensure the results of the Bradford 
were accurate, a Coomassie stain was performed.  30µL of BSA (1µg/µL) and 30µL of 
SDS loading buffer were mixed to create a BSA standard solution with a concentration of 
0.5µg/µL.  8µL (4µg), 12µL (6µg), 16µL (8µg), and 20µL (10µg) were loaded into the 
wells of a hand-poured SDS-PAGE gel to serve as protein concentration comparisons for 
the eluted proteins from the native purification.  2 and 4µL of eluted protein were also 
loaded.  The same Coomassie protocol was followed as listed above.  Once destained, the 
bands of the standards were compared to the bands of eluted protein to estimate the 
concentration of the eluted protein.   
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TrxR Drug Treatment Assay 
 Purified TrxR was used to determine the affects of different concentrations of 
auranofin and auranofin analogs on the enzyme’s activity.  The total reaction volume was 
100µL.  The reaction was carried out in a 100µL cuvette that was heated to 37°C in a 
Thermo Scientific NanoDrop 2000c Spectrophotometer.  13.3µL of 15mM Ellman’s 
Reagent (DTNB) (final concentration of 2mM) was added to a microfuge tube, followed 
by a variable amount of 0.1M KPO4 buffer warmed to 37°C in a heat block.  (The amount 
was variable because it depended on the concentration of the purified TrxR isoform.  The 
isoforms purified had different concentrations, and so different amounts of buffer were 
needed to bring the total volume of the reaction up to 100µL).  The two reagents were 
mixed.  Then, a 100nM enzyme mix of TrxR and Trx proteins was added to the tube and 
mixed as well.  The final thing mixed into the tube was 1µL of either DMSO or drug.  
This mixture was then transferred to the cuvette and incubated for 1-2 minutes in the 
NanoDrop.  The NanoDrop was blanked, and 10µL of 2mM NADPH (final concentration 
of .2mM) was added to the cuvette and pipetted up and down several times.  The cuvette 
was placed back into the NanoDrop and the activity was measured every 30 seconds for 3 
minutes at 412nm.   
 Eight concentrations of drug were tested: .1nM, 1nM, 10nM, 50nM, 100nM, 
250nM, 500nM, and 1µM.  The drugs were solubilized in DMSO, and so DMSO was 
used as the negative control.  Treatments for auranofin were carried out in duplicate, and 
those for the analogs in triplicate.  All of the reagents except the buffer and drug/DMSO 
were kept on ice.  The buffer was heated to 37°C and the drug/DMSO were kept at room 
temperature.   
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IC50 Calculation for Auranofin and Auranofin Analogs 
 The absorbance data obtained from the drug treatment assays was transferred to 
Excel and used to calculate the nmols of NADPH consumed per minute, a measure of the 
TrxR protein enzymatic activity.  To account for any variability and human error, these 
values were normalized to the values obtained from that trial’s DMSO treatment.  So the 
final data were presented as percent activity as compared to DMSO, with DMSO 
treatment corresponding to 100% activity.  The values were input into GraphPad Prism 
software, and IC50 curves and values were generated and calculated, respectively.   
qPCR Analysis of Isoform Levels Post-Drug Treatment 
 Drug treatment.  An 8µL sample was taken from a 10mL tube containing T. 
vaginalis G3 cells and placed onto a hemocytometer to determine what volume contained 
2x106 cells.  This volume was added to three separate tubes with enough media present so 
that the total volume would be 10mL.  One tube had 5µL of DMSO added, another had 
2.5µL of a 1mM stock of auranofin added (0.25µM final concentration), and the third had 
5µL of the 1mM auranofin stock added (0.5µM final concentration).  The cultures were 
grown overnight at 37°C.  A hemocytometer was once again used to ensure that the drug 
treatments worked on the cells.  The cells were spun for 5 minutes at 1,000xg and had the 
supernatant removed, followed by a wash with 10mL of PBS.  Another 5-minute spin at 
1,000xg was performed.  The supernatant was removed, and the pellet stored at -80°C.  
The drug treatments were completed in triplicate.   
 RNA isolation.  RNA was isolated from G3 cells treated with DMSO, 0.25µM 
auranofin, and 0.5µM auranofin using the TRIzol® Reagent RNA Isolation Procedure 
33 
 
from invitrogen.  Once isolated, RNA concentrations were determined by using a Thermo 
Scientific NanoDrop 2000c Spectrophotometer, and the samples were stored at -80°C.   
 Reverse transcription.  RNA isolated from G3 cells that underwent the three 
different treatment conditions mentioned above was reverse transcribed.  First, the RNA 
concentrations calculated were used to determine what volume contained 1µg of RNA.  
Because, the concentrations were so high, they were first diluted 1:10, and the 
concentrations of these dilutions were used to determine what volume contained 1µg of 
RNA.  Enough RNase-free H2O was added to bring the total volume up to 8µL.  To this 
tube, 1µL of 10X DNase I Buffer and 1µL of DNase I were added, and the mixture was 
incubated at room temperature for 15 minutes.  1µL of 25mM EDTA was added, and the 
the tube was incubated on a 65°C heat block fro 10 minutes, followed by an incubation 
on ice for 5 minutes.  1µL of oligo DT (0.5µg/µL) and 1µL of 10mM dNTPs were added.  
This was followed by another incubation cycle of 65°C for 10 minutes, and ice for 5 
minutes.  Next, 4µL of 5X Superscript Buffer, 1µL of 0.1M DTT, 1µL of RNase Out, and 
either 1µL of Superscript or H2O were added.  (One of the treatment sets was reverse 
transcribed in duplicate without the addition of reverse transcriptase to serve as a 
negative control).  The tubes were placed in a PCR machine programmed for 50°C for 1 
hour, 70°C for 15 minutes, and 10°C overnight.  1µL of RNase H was added, followed by 
a 37°C incubation for 20 minutes.  The mixture was then diluted 1:10 for subsequent 
qPCR analysis.   
 qPCR analysis.  The reverse transcribed cDNA of the G3 cells exposed to the 
three treatment methods from above was used to analyze levels of TrxR isoform levels.  
The total reaction volume was 50µL.  To PCR tubes, 25µL of iTaq 2X, 1µL of forward 
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primers, 1µL of reverse primers, 13µL of RNase-free H2O, and 10µL of cDNA were 
mixed together on ice.  Actin was used as the reference gene, since its levels are known 
to not be affected by auranofin treatment.  The samples were loaded into an MJ Research 
DNA Engine Opticon™ 2 qPCR machine, and the levels of the TrxR isoforms were 
analyzed across the three treatment methods and the triplicate treatments.   
 The data was transferred to excel, where values for average CT, ΔCT, ΔΔCT, and 
fold change were calculated.   
Proteomic Analysis 
 Drug treatment.  T. vaginalis G3 cells were treated under the same conditions as 
described above, except treatments were performed in duplicate, not triplicate.   
In-solution digest.  175µL of Lysis Buffer (6.4M urea, 200mM NH4HCO3, pH 
7.5) was used to resuspend pellet.  Mixture was transferred to a microfuge tube and cells 
were lysed by incubating for 1 hour at room temperature.  Following the incubation, cells 
were quickly sonicated (3-5 short bursts) and spun at 16,000xg for 10 minutes.  
Supernatant was collected into two microfuge tubes—100µL to continue with the 
protocol, and the rest for quantification of protein using a Bradford assay as mentioned 
above.  0.5µL of 1M DTT (5mM final concentration) was added to the tube, and the 
mixture was incubated for 1 hour at room temperature (can be done with cell lysis step, 
above).  Next, 15µL of iodoacetamide (IAA) (15mM final concentration) were added, 
and the mixture was incubated for 30 minutes at room temperature in the dark.  
Following that, the urea was diluted out with the addition of 3 volumes (300µL) of 
50mM NH4HCO3 (1:4 dilution).  Using the concentration amount obtained from the 
Bradford, enough Trypsin was added to produce a sample:Trypsin ration of 10:1.  Sample 
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was incubated with Trypsin overnight at 37°C.  After the incubation, 1-part Sample 
Buffer (2% trifluoroacetic acid (TFA) in 20% acetonitrile(ACN)) was added to 3-parts of 
the overnight sample and Trypsin digest.   
Thermo Scientific Pierce® C-18 Spin Columns were prepped by adding 200µL of 
Activating Solution (50% methanol) to wet column walls and resin.  The column was 
spun down at 1,500xg for 1 minute, and the flow-through was discarded.  Activations 
step was repeated once more.  Next, 200µL of Equilibration Solution/Wash Buffer (0.5% 
TFA in 5% ACN) was added, and the column was centrifuged at 1,500xg for 1 minute.  
The flow-through was discarded.  This last step was repeated once more.   
Sample was added to column, and the column was attached to a fresh collection 
tube.  The column was centrifuged at 1,500xg for 1 minute, and the flow-through was 
saved.  Column was washed by adding 200µL of Wash Buffer and spinning at 1,500xg 
for 1 minute.  Flow-through was discarded.  Wash step was repeated.  Protein was eluted 
by adding 20µL of elution buffer (70% ACN) and spinning the column at 1,500xg for 1 
min.  Elution was repeated for a total volume of 40µL.  The entire protocol starting at the 
equilibration step was repeated 3x, for a total eluted volume of 160µL.  The ACN was 
lyophilized off using a Labconco FreeZone 12 Plus.  Protein was then resuspended in 
high-performance liquid chromatography (HPLC) grade H2O with 0.1% formic acid to 
get a final concentration of about 0.5-0.6µg/µL (usually between 30-50µL).  The sample 
was then added to a mass spectrometry vial for analysis.   
Mass spectrometry analysis.  An Orbitrap Fusion™ Tribrid™ Mass 
Spectrometer from Thermo was used to analyze the proteomes of the G3 cells exposed to 
the three treatment methods listed above through tandem mass spectrometry.  Peptides 
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were fragmented using three different methods: collision-induced dissociation (CID), 
higher-energy collisional dissociation (HCD), and electron-transfer dissociation (ETD).  
Originally, to detect more peptides, the m/z range that the Orbitrap detects was divided 
into a low-mass group (m/z=300-600) and high-mass group (m/z=600-1,800).  There 
wasn’t enough of one of the samples to do this dual range, however, and so the analysis 
focused on the low-mass range.   
The data obtained form the Orbitrap was input into the proteomics software 
PEAKS to sequence the peptides and identify and quantitate the proteins.  Data was 
normalized to actin.  Data generated from PEAKS was used to graph whole-proteome 
changes in response to the different drug treatments.  Aside from the quantities of peptide 
fragments that were present in the three fragmentation methods, PEAKS also took 3 
Surveys to determine overall peptide quantities.  These survey values were averaged to 
determine how specific protein levels changed in response to drug treatment, when 
compared to DMSO.  Levels were normalized to DMSO and presented as a group profile 
ratio.   
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Chapter 3: Results 
 
 
Pilot Inductions of TrxR Isoforms 
 There are five different isoforms of TrxR in T. vaginalis (Table 2)—for 
convenience, the isoforms will be referred to by the first three digits of their gene 
accession number (bolded). 
 
   
 
Our collaborator had all five isoforms cloned into the pET-15b vector.  These five 
constructs were subsequently transformed into TOP10F’ cells to proliferate.  Three 
colonies were picked for each construct (designated a, b, and c), and the DNA was 
miniprepped.  The constructs were cut using Nde1 and BamH1-HF.  The digested DNA 
Table 2.  List of the five different TrxR isoforms present in T. vaginalis, as well as 
their molecular weight and gene length. 
38 
 
was run out on a gel to confirm the presence of the isoform DNA within the 
plasmid constructs.  All three colonies from the five isoforms showed bands of the 
expected size.  
We chose to do pilot protein expression studies using the two colonies of each 
construct that appeared to contain the most DNA.  Since that meant 10 colonies total, 
several rounds of Westerns were performed to examine them all.   
 Figure 3 shows the results of the pilot inductions, with cell cultures collected at 
two time points following addition of IPTG: 4 and 24 hrs.  A sample was also collected 
just prior to addition of IPTG to serve as a negative control.  Looking at the blots, it is 
observed that for many of the colonies, the negative lane had the most prominent band.  
This is owed to the cell line used to express the isoforms, BL21 DE3.  These cells result 
in leaky expression prior to IPTG addition.  Before induction, colonies were grown up 
overnight.  From these overnight colonies, 1mL was added to fresh media and grown up 
until the correct OD was reached.  It was then that IPTG was added.  The negative 
samples were taken from the overnight colonies, however.  These cells had been slowly 
producing protein for over a day, resulting in the prominent band in the negative lanes.   
Before using BL21 DE3 cells, BL21 cells were used, but it was found that many 
of the isoforms were inadequately expressed in this cell line.  Before switching over to 
BL21 DE3 cells, however, isoform 125 had been expressed, and so this is what was used 











Figure 3.  Western blot analysis of pilot TrxR isoform expression in E. coil strain 
BL21 DE3.  Anti-His antibody probe used.  Cell cultures collected 4 and 24hrs after 
IPTG induction.  Negative lanes contain samples collected prior to IPTG addition.  
Positive lanes contain a TrxR 125 that had been previously expressed. 
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Protein was present for all colonies tested, although TrxR was present in much 
greater abundance in isoforms 474 and 125 than in the other three.  Looking at 474 first, 
colony “a” had better induction levels than colony “c”.  While for isoform 125, both 
colonies yielded high protein levels.  For both of these higher expressing isoforms, it 
appears that the 4hr induction resulted in maximum amount of protein than the 24hr 
induction.   Looking at all five colonies, it seems as if the 4hr induction resulted in higher 
protein yields than the 24hr induction. 
The other three isoforms had levels of TrxR much lower than those of 125 and 
474, and so the pilot inductions had to be repeated.  Repeatedly, though, proteins levels 
remained low.  Culture conditions were altered to see if different temperatures might 
produce more optimal inducing conditions, but these attempts saw no change in levels 
produced.  Cell lines were switched for a second time in an effort to produce different 
results.  BL21 DE3 RIPL cells were used, leading to increases in the amounts of protein 
produced of isoforms 281 and 348.  Isoform 240 never expressed adequate amounts of 
protein, preventing any further work. 
Large-Scale Purification of TrxR Isoforms 
 Based off the data from the Westerns, isoforms 474 and 125 yielded the highest 
amounts of protein by a large margin, even after isoforms 348 and 281 were moved to the 
RIPL strain of cells.  Because of this, and because we hadn’t been able to induce decent 
amounts of protein from the other three isoforms, we decided to proceed first with these 
two better-inducing isoforms.   
 BL21 DE3 cells were grown up in 250mL cultures for large-scale inductions in 
order to purify large amounts of protein for future drug assays.  After inducing for 4hrs, 
the proteins were purified by gravity filtration using Ni-NTA agarose beads under native 
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conditions using a step gradient with increasing concentrations of imidazole to elute.  
Following that, SDS-PAGE gels were run, followed by Coomassie stains to ensure that 
the purification had worked properly and to determine which elution contained the 
highest amounts of protein (Figures 4 and 5).   




Figure 4.  Coomassie stain of TrxR 474 protein purification fractions.  A step 
gradient of increasing concentrations of imidazole was used to elute the protein.  
Protein was eluted with 300mM of imidazole twice (lanes 9 and 10).  Protein was 






Both purifications were successful.  For 474, the greatest amount of protein was 
eluted with 100mM imidazole.  For 125, the greatest amount of protein was eluted with 
150mM imidazole. 
Despite having shown good induction levels during the pilot inductions using the 
RIPL cells, the large-scale inductions of isoforms 348 and 281 struggled to yield similar 
results.  Despite repeated attempts, large-scale inductions of 281 never resulted in enough 
protein to proceed with assays.  For isoform 348, eventually enough protein was 
successfully induced large scale so that assay work could proceed.  The protein first had 
to be concentrated, however.  
Figure 5.  Coomassie stain of TrxR 125 protein purification fractions.  A step 
gradient of increasing concentrations of imidazole was used to elute the protein.  
Protein was eluted with 300mM of imidazole twice (lanes 9 and 10).  Protein was 
purified from E. coli under native conditions.   
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 Quantifying purified TrxR.  A Bradford assay was performed to quantitate 
amount of protein eluted.  Two elutions for each isoform were tested to see how 
comparable the concentrations were: 100mM and 150mM for 474; and 150mM and 
200mM for 125.  µM amounts were only calculated for the elutions with the highest 
concentrations.  For 474, the 100mM elution had a concentration of .87 µg/µL, (27µM).  
For 125, the 150mM elution had a concentration of .75 µg/µL, (23µM).  Once 
concentrated, the concentration of 348 was determined to be 2.22µg/µL (58.4µM).   
 Because the elutions didn’t look very clean, a Coomassie was also used to 
quantify the amounts of isoforms 474 and 125 (Figure 6).  Different amounts of BSA 
standards (4, 6, 8, and 10µg) were used to estimate the amount of enzyme for 474 and 
125.  It should be noted that some of the prepared BSA solution was lost before all of the 
standards were pipetted into the wells.  This is why the lane for the standard of 10µg 
contains less protein than that of the lane for 8µg.  Two separate volumes of isoforms 
were loaded (2 and 4µL).  The results helped to validate the results obtained from the 








 We began enzymatic assays with the purified isoforms to see how auranofin 
affects the different isoforms and if analogs of the drug have a stronger inhibitory effect 
on the enzymes.   
 Auranofin assays.  The purpose of testing auranofin analogs against the isoforms 
was to potentially find any drugs with similar or greater efficacy than auranofin that 
Figure 6.  Coomassie stain quantification of purified TrxR isoforms, 474 and 125, 
using BSA standards.  Loaded either 2 or 4µL of the isoforms and compared amounts 
to 4, 6, 8, and 10µg of BSA.  A previously purified TrxR of a known concentration 
was used as a positive control. 
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could then be further tested to inspect if they result in less side effects.  If so, that would 
make the analogs better drug candidates and further testing could proceed with them 
instead.  Because of this, auranofin assays first needed to be conducted in order to have a 
baseline for which to compare the results of the analogue tests. 
 The assays were carried out small scale using five components (Table 3).  The 
total volume of the assay was 100µL.  DMSO was used as a control because all of the 
drugs were suspended in it.  The drug concentrations used were .1nM, 1nM, 10nM, 
50nM, 100nM, 250nm, 500nM, and 1µM.  1µM was used as the highest concentration 
because previous work by Hopper et al. had shown that this concentration of auranofin 
was very potent at inhibiting enzymatic activity.  .1nM was chosen as the lowest dosage 
because we wanted a concentration that correlated to negligible amount of drug.  In this 
way, the eight drug concentrations spanned a comprehensive spectrum.  And as such, 
each assay set consisted of testing the isoform against 9 compounds (DMSO plus the 8 




 DTNB gets reduced by Trx, producing 2 TNB molecules, which are yellow.  As 
the reaction proceeds, more and more yellow is produced as more and more DTNB is 
reduced by Trx.  The breakdown of DTNB into TNB, and subsequent yellow production, 
Table 3.  Components of the drug activity assay. Total volume is 100µL.   
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results in a change in absorbance.  This absorbance change is what was monitored as the 
reaction proceeded.  Because NADPH is the initial electron source, and because its 
starting amount is known, it is possible to use the change in absorbance (production of 
TNB molecules) to calculate the amount of NADPH consumed.  This amount is what was 
used to gauge how active the isoforms were.  Since DMSO was the negative control, all 
values were normalized to it.  This meant that in the end, data was in the form of 
%DMSO activity, with DMSO-treated isoforms having 100% activity.  This data was 
entered into GraphPad Prism to generate IC50 curves and to calculate IC50 values for 474 
and 125 (Figures 7 and 8).  For TrxR 474, auranofin’s IC50 = 255nM.  For TrxR, 
auranofin’s IC50 = 397nM.  From this, we can see that auranofin is more effective against 
isoform 474, bringing its activity down to 50% at a lower concentration.   
 Comparing these results to those previously observed by Hopper et al. (2016), a 
difference in IC50 values is seen.  They reported a value far lower (IC50=80nM), than our 
calculated value.  This difference might be the result of differences in assay conditions.  
Their assay was done on a larger scale (1mL total volume), and this might account for the 
different IC50 values observed.  Some variation on protein concentrations tested might 








Figure 7.  IC50 graph of auranofin’s effect on the activity of TrxR 474.  IC50=255nM.  
Figure 8.  IC50 graph of auranofin’s effect on the activity of TrxR 125.  IC50=397nM.  
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IC50 data for isoform 348 could not be calculated because the protein was found to 
have very little activity.  Looking back at Figure 2, it can be seen that when examining 
the active sites of the five isoforms, only isoforms 474, 125, and 281 have the correct 
amino acid sequence (Mentel et al., 2008).  This would account for the observed 
inactivity of isoform 348 in the assay, since it and isoform 240 both have non-active 
active sites.  To confirm this inactivity, another round of large-scale inductions was 
performed and more of isoform 348 was purified.  Again, however, no activity was 
observed, and so the analog assays were only carried out with isoforms 474 and 125.   
Analog Assays.  The analog assays were carried out in the same manner as the 
auranofin assays.  The same eight concentrations of drug were tested, and DMSO was 
still used as a negative control.  The only difference was that analog assays were carried 
out in triplicate, rather than in duplicate.   
Two different analog libraries were screened against isoforms 474 and 125.  From 
the first library, five drugs were tested. These were analog 1, analog 3, analog 4, analog 
5, and analog 7.  The second library consisted of 15 drugs (LEAU 1-15).  Each of these 
drugs was tested against TrxR 474 at 1µM, since that was the highest concentration of 
auranofin used in the previous assays.  Full-scale assays on isoforms 474 and 125 were 
conducted using only the analogs whose inhibition of enzymatic activity was either on 
par or greater than that of auranofin.  There were only three analogs from this second 
library that met those criteria: LEAU 8, LEAU 9, and LEAU 14.  So in total, 8 analogs 








Figure 9.  IC50 graph of analog 1’s effect on the activity of TrxR 474.  IC50=270nM.  







Figure 11.  IC50 graph of analog 3’s effect on the activity of TrxR 474.  IC50=6.28µM.  







Figure 13.  IC50 graph of analog 4’s effect on the activity of TrxR 474.  IC50 = 831nM.  







Figure 15.  IC50 graph of analog 5’s effect on the activity of TrxR 474.  IC50=2.35µM.  







Figure 17.  IC50 graph of analog 7’s effect on the activity of TrxR 474.  IC50=24.74µM. 







Figure 19.  IC50 graph of analog LEAU 8’s effect on the activity of TrxR 474.  IC50=95nM.  







Figure 21.  IC50 graph of analog LEAU 9’s effect on the activity of TrxR 474.  IC50=135nM.  







Figure 23.  IC50 graph of analog LEAU 14’s effect on the activity of TrxR 474.  IC50=210nM.  
Figure 24.  IC50 graph of analog LEAU 14’s effect on the activity of TrxR 125.  IC50=414nM.  
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 A summary of the IC50 values for auranofin and the various analogs in regards to 
isoforms 474 and 125 is provided in Table 4.  Here we can see that certain drugs affected 
the isoforms differently, and inhibited the activity of one much more greatly than it did 
the other.  As such, it’s best to discuss the effect the drugs had on the isoforms separately. 
 Looking at TrxR 474 first, we can see that the effects of analogs 1 and LEAU 14 
were fairly comparable to those of auranofin.  Analogs LEAU 8 and 9, however, were 
more effective at inhibiting the enzymes activity, with LEAU 8 being the most effective 
of the two. 
When looking at TrxR 125, we see that the only analog that was comparable to 
the effects of auranofin was LEAU 14.  And just like TrxR 474, 125’s activity was most 
inhibited by analogs LEAU 8 and 9.  Unlike TrxR 474, however, 125 was most greatly 




qPCR Analysis of Isoform Levels  
 There are five isoforms of TrxR present within T. vaginalis, but that doesn’t mean 
that all of the isoforms are transcribed equally.  Transcript levels might even be 
influenced by exposure to auranofin.  The organism could possibly modulate 
transcription of certain isoforms to deal with the stress caused by drug treatment.  




Knowing this would be beneficial to understanding ways in which T. vaginalis might 
respond to auranofin.   
 Three tubes of G3 cells were treated with either DMSO (negative control), .25µM 
auranofin, or .5µM auranofin.  Cells were treated with a high and low concentration of 
the drug to see if it would respond differently to varying levels of stress.  These drug 
treatments were carried out in triplicate.  After treatment, total RNA was isolated from 
the cells.  This RNA was subsequently reverse transcribed to produce cDNA.  During the 
reverse transcription, one set of tubes didn’t have have reverse transcriptase added, and 
this set served as the negative control.  Once the cDNA was obtained, the real-time PCRs 
could be carried out.  Before that, however, test PCRs were performed with the five 
different isoforms to determine what annealing temperature was best for them.  A 
temperature gradient was tested ranging from 57.3°C-62.0°C.  For all five isoforms, the 






 The reference gene used was actin.  Its CT values were used to calculate ΔCT 
values.  The ΔCT values of the DMSO treated cells were averaged across the triplicate 
treatments and used to compare basal mRNA levels of the five isoforms by looking at 
fold changes in expression (Figure 25).  The isoform with the lowest basal levels (TrxR 
281), was used as a reference to determine the levels of the other four isoforms.  The data 
shows that isoforms 348, 281, and 240 all present in the lowest amounts.  The levels of 
isoform 125 are around 80- and 70-fold higher than these three isoforms, while the levels 
of isoform 474 are over 240-fold higher.   
 






From the ΔCT values,  average ΔΔCT values and fold-change amounts across the 
triplicate treatments were calculated for G3 cells treated with 0.25µM and .5µM 
auranofin.  Figures 26-30 show how mRNA levels changed for the five TrxR isoforms in 
relation to DMSO across the two drug treatments. 
 
Figure 25.  Comparison of basal mRNA levels of the five TrxR isoforms from G3 cells 





Figure 26.  Comparison of mRNA levels of TrxR isoform 474 in response to drug treatment.  
DMSO levels are considered basal, and so are given a value of 1.  The values for the drug-
treated cells are in relation to DMSO-treated cells.  G3 cells treated with .25µM auranofin had 





Figure 27.  Comparison of mRNA levels of TrxR isoform 125 in response to drug treatment.  
DMSO levels are considered basal, and so are given a value of 1.  The values for the drug-
treated cells are in relation to DMSO-treated cells.  G3 cells treated with .25µM auranofin had 





Figure 28.  Comparison of mRNA levels of TrxR isoform 348 in response to drug treatment.  
DMSO levels are considered basal, and so are given a value of 1.  The values for the drug-
treated cells are in relation to DMSO-treated cells.  G3 cells treated with .25µM auranofin had 





Figure 29.  Comparison of mRNA levels of TrxR isoform 281 in response to drug treatment.  
DMSO levels are considered basal, and so are given a value of 1.  The values for the drug-
treated cells are in relation to DMSO-treated cells.  G3 cells treated with .25µM auranofin had 






From these figures (data summarized in Table 6), we can see that no general 
trend was shared by the five isoforms.  There was no consistency in how mRNA levels 
changed in regards to the concentration of drug treatment, and the fold changes of the 
mRNA levels also show variance.  Isoform 474, the isoform with the greatest amount of 
basal mRNA, had an almost negligible fold increase for the lower concentration drug 
treatment, and a little over a half-fold increase for the higher concentration treatment.  
This differs markedly from isoform 125, the isoform with the second highest levels of 
basal mRNA, and the isoform that experienced the highest fold change.  The lower 
Figure 30.  Comparison of mRNA levels of TrxR isoform 240 in response to drug treatment.  
DMSO levels are considered basal, and so are given a value of 1.  The values for the drug-
treated cells are in relation to DMSO-treated cells.  G3 cells treated with .25µM auranofin had 
a fold change of 1.559.  G3 cells treated with .50µM auranofin had a fold change of 1.592.   
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concentration of drug resulted in a half-fold increase, while the higher concentration 
produced an almost 1.5-fold increase.  Isoform 348 was the only one that experienced a 
fold decrease between the low and high concentration drug treatments.  The final two 
isoforms, 281 and 240, shows similar trends of experiencing progressively increased fold 
increases with increased drug concentration.  These values show that treatment with 
different auranofin doses affects the isoforms differently, in a manner independent of the 





Table 6.  Averages of ΔΔCT and fold-change values of the five TrxR isoforms when 
treated with two concentrations of auranofin from qPCR results.   
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Proteome Analysis by Mass Spectrometry  
 Changing mRNA levels can sometimes be indicative of changing protein levels, 
but that isn’t always the case, due to post-translational modifications.  To further test how 
auranofin treatment might affect TrxR isoform levels, mass spectrometry was used to 
conduct a whole proteome analysis on treated and untreated cells.  Again, G3 cells were 
treated with either DMSO, .25µM auranofin, or .5µM auranofin.  This time, tests were 
carried out in duplicate.  An in-solution digest was carried out to breakdown the proteins 
into peptides.  Following this, the peptides were isolated and prepped for the Orbitrap 
Fusion™ Tribrid™ Mass Spectrometer where they were analyzed by tandem mass 
spectrometry.  Three different fragmentation methods (CID, HCD, and ETD) were used 
to identify peptides.  The proteomics software PEAKS was used to identify and quantitate 
proteins in our samples using the fragment data.  Protein quantities were normalized to 
actin levels.   
 Figure 31 represents the whole-proteome analysis that was conducted.  Each blue 
dot represents one peptide, and the figure compares how abundance of peptides compared 
between both treatments and across the different treatment conditions.  While the whole-
proteome analysis provided expansive information, the data that was most relevant to us 
was how TrxR isoform levels responded to the different concentrations of drug.  Next, we 
also looked at how other cellular redox proteins were affected as well.  When examining 
the data, one can see how the abundance of various peptides changes depending on what 
the cells were treated with.  When the DMSO-treated cells from treatments 1 and 2 are 
compared, the scatter plot is very linear.  This is what we would hope and expect to see, 
because many of the same peptides should be present in untreated G3 cells in very similar 
abundance.  The linearity disappears most dramatically when DMSO-treated cells are 
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compared to cells treated with .5µM auranofin.  Here, the scatter plots are much more 
dispersed.  This is due to changes in peptide abundance between the two treatment 
conditions, indicating that drug treatment does lead to a change in protein levels in T. 





Figure 31.  Whole proteome analysis of two treatments of G3 cells treated with DMSO, 
.25µM auranofin, or .5µM auranofin.  “-1” and “-2” denote treatment 1 and treatment 2.  
Each blue dot is one peptide.  Graph shows different comparisons based on peptide mass and 
abundance between both treatments and all three treatment conditions.  A more linear scatter 
plot indicates greater similarity in peptide abundance between treatment conditions.  A more 
disorganized scatter plot indicates decreased similarity in peptide abundance between 
treatment conditions, and thus a difference in protein levels. 
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 Looking specifically at cellular redox proteins, group profile ratios were used to 
compare changes in protein levels in response to drug treatment.  These ratios represent 
the abundance of the proteins under the two auranofin treatments, normalized to the 
abundance present in the DMSO treatment (the abundance assumed to represent basal 
levels).  Starting with the five TrxR isoforms, only two of them, 474 and 125, were 
detected by the mass spectrometer.  Figures 32 and 33 show the changes in abundance 
for these two isoforms across the two drug treatments when normalized to DMSO.  From 
this data, we see that the isoforms differed in the way their protein levels responded to 
auranofin treatment.  While both isoforms experienced a decrease in levels when treated 
with .25µM of the drug, it was only isoform 125 that experienced an increase in levels for 
both replicates conducted when treated with .5µM of the drug.  It should also be noted 
that the higher concentration of drug resulted in a much larger fold increase in protein 
amount for both isoforms for treatment 1 when compared to treatment 2.  This is likely 
due to the increased potency of the high concentration of auranofin at killing the cells.  
Because the cells treated at the higher concentration are under greater stress and many are 
dying, their intracellular protein levels might be expected to be in a greater state of flux.  
Since actin was used to normalize the data, it is very possible that at the high-
concentration drug treatment, actin protein levels are not uniform across cells, resulting in 






Figure 32.  Comparison of protein levels of TrxR isoform 474 across two separate drug 
treatments. Cells were treated with two concentrations of auranofin. DMSO levels are 
considered basal, and so are given a value of 1.  The values for the drug-treated cells are in 







 Besides the TrxR isoforms, we also looked at how various other cellular redox 
proteins (Trxs, TrxPs, alcohol dehydrogenases, and superoxide dismutases) responded to 
drug treatment (Table 7).  For most of these proteins, the same trend seen for the 
isoforms, where the higher concentration of drug from the first treatment saw a higher 
fold change compared to the second, was observed.  There was no clear consensus when 
looking at the Trxs.  The TrxPs, however, both had the highest levels of protein in cells 
exposed to .5µM auranofin and the lowest in cells exposed to .25µM auranofin.  The 
superoxide dismutases demonstrated a similar pattern, with one protein being 
Figure 33.  Comparison of protein levels of TrxR isoform 125 across two separate drug 
treatments. Cells were treated with two concentrations of auranofin. DMSO levels are 
considered basal, and so are given a value of 1.  The values for the drug-treated cells are in 
relation to DMSO-treated cells.   
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dramatically elevated when treated with .5µM of drug.  For the dehydrogenases, on the 
other hand, drug treatment resulted in decreased levels across the board.  
If looked at broadly, the data does show two trends. The first, .25µM auranofin 
treatment led to decreased amounts of protein compared to DMSO for all of the proteins 
listed.  Why the lower concentration of drug led to this drop in protein levels of these 
redox proteins remains uncertain.  It might be because this dosage was less acute.  
Perhaps if cells were treated longer than 24 hours, similar results to the higher 
concentration would be observed.  The second, compared to the .25µM treatment, most 
of the proteins saw an increase in protein levels during the .5µM treatment.  Again, the 
reason why that was remains to be determined, and again, this general increase in levels 
from .25µM to .5µM treatment was not present when looking at changes between the 




Table 7.  Comparison of ratios of various cellular redox proteins among T. vaginalis 
cells treated with DMSO or different concentrations of auranofin.  Data is from two 
replicates (T1 and T2).  
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Chapter 4: Discussion 
 
 
 Finding a new means to treat Trichomoniasis would afford comfort in knowing 
that possible metronidazole-resistant strains could still be treated.  Not only that, but we 
would have a new drug to treat a highly prevalent sexually transmitted infection with 
dangerous ties to HIV.  Auranofin, an FDA-approved oral drug currently used to treat 
severe cases of rheumatoid arthritis, appears to be a strong candidate to target 
Trichomonas vaginalis, killing the organism and treating trichomoniasis.   
 Our studies confirmed the effectiveness of auranofin, and several of its analogs, in 
targeting the two major TrxR isoforms in T. vaginalis, inhibiting both enzymes.  Activity 
assays showed that the addition of drug decreased the rate at which DTNB is reduced in a 
dose-dependent manner, a process dependent on TrxR activity.  The fact that analogs of 
auranofin were also shown to be effective at inhibiting enzymatic activity of these crucial 
proteins allows for an expansion of the candidate drug pool.  Despite its FDA approval, 
several symptoms are linked to auranofin usage.  Knowing that auranofin has analogs 
with similar or lower IC50 values allows for more drugs to be used in clinical tests.  It 
might turn out that these analogs don’t produce any of the symptoms associated with 
auranofin treatment.  Or, if the symptoms do manifest, they might be less commonly 
seen, or less severe.  Regardless, this would mean that the analogs are actually better drug 
candidates than auranofin, and future studies can proceed with them instead.   
Our results showed that out of the analogs tested, both LEAU 8 and 9 had IC50 
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values for TrxR isoforms 474 and 125 that were lower than those of auranofin.  Two 
other analogs, analog 1 and LEAU 14, were also shown to have comparable IC50 values 
to those of auranofin.  Even though LEAU 8 and 9 performed the best, future studies 
should incorporate all four analogs.  It might be revealed that symptoms might still be 
present, or be even more prevalent or severe, in the two best-performing analogs.  And it 
could be that the two comparable analogs actually have no symptoms associated with 
usage, making them the much better choices for future studies.   
 Regardless of what future tests reveal, our results have shown the effectiveness of 
auranofin and its analogs of inhibiting the two major isoforms of TrxR in T. vaginalis. 
 When searching for new methods to treat an STI, it’s always good to look towards 
the future.  Resistance to metronidazole has already been observed, and it’s probable that 
T. vaginalis might someday develop resistance to auranofin as well.  Preemptively 
looking for ways in which resistance might develop could allow us to tailor current 
treatment methods to curtail that resistance from developing.  Anticipating resistance 
could also allow us to focus on searching for or developing drugs that would be effective 
on these resistance strains.  
 T. vaginalis contains five isoforms of TrxR, but it’s uncertain whether the 
isoforms are all expressed in equal amounts.  It may be that only some of the isoforms are 
present in high amounts, or in the same cellular location, rather than all.  The presence of 
five different isoforms could also be a defense mechanism.  Under stress, the organism 
might upregulate the transcription or translation of certain isoforms.  It would be 
beneficial to know this, as this could be a means by which T. vaginalis might try to 
counteract drug treatment.   
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The data from the drug assays would also be more useful if we had a bigger 
picture to go off of.  We know how effective auranofin is against the isoforms, and how it 
targets them.  The results showed that it was more effective against isoform 474 than 125.  
Knowing how the transcript levels of these proteins are modulated in response to drug 
treatment would better allow us to contextualize the assay results.  If drug treatment 
increases amounts of 125 but not 474, then auranofin being a more potent inhibitor of 474 
won’t really matter because of the greater abundance of 125.  
The results from the qPCR analysis showed that basal mRNA levels of the five 
isoforms aren’t affected very differently in response to drug treatment.  If anything, the 
results showed that all five isoforms have a mild fold-increase in response to auranofin, 
but no one isoform experienced greatly elevated levels of transcription.  What the qPCR 
results did show, though, is that basal mRNA levels of the five isoforms varied greatly.  
Isoforms 474 and 125 had much higher levels when compared to the three other isoforms, 
with the levels of isoform 474 being the highest of all, by a very large margin.  When 
compared to how the inductions and purifications of the five isoforms turned, the basal 
mRNA data helps to reassure what was seen.  The two isoforms with the highest basal 
levels were easily expressed and purified, while the three with the lowest basal levels 
were not.  We can thus be confident that the drug assays were performed on the TrxR 
isoforms most important to the organism, and that data is not missing for any other 
isoform of apparent importance.  We can put more trust in this belief, considering that 
mRNA levels saw no major change post-drug treatment.   
This is only a partial story, however.  Various post-translational modifications 
might result in protein levels of the five isoforms that differ from what was seen for the 
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mRNA levels.  Just because substantial differences in mRNA levels weren’t observed, 
doesn’t mean that the same will hold true for protein levels, and so mass spectrometry 
was performed to examine how protein levels responded to drug treatment.  Important to 
note is that the mass spectrometer only detected isoforms 474 and 125, validating the 
qPCR data.  We saw that when treated with .25µM of auranofin, both isoforms saw 
decreases on their protein levels when compared to DMSO-treated cells.  The exact 
reason for this decline is unknown.  It might be due to .25µM being a low enough 
concentration that doesn’t outright kill the cells, but instead causes them to experience 
some stress.  If T. vaginalis isn’t overtly stressed, but still under some duress, it could be 
that other proteins, ones not focused on here, were upregulated.  They may not focus on 
combatting oxidative stress, but instead nutrient storage.  Further studies would need to 
be conducted to delve into this drop in protein levels further. 
Unfortunately, when looking at cells treated with .50µM of auranofin, there is too 
much of a difference between the results of the two replicate treatments conducted to 
have a clear understanding of how the levels of isoforms 474 and 125 are responding.  
The mass spectrometry analysis would need to be redone to get a clearer picture of how 
the higher concentration of drug is affecting isoform levels.   
Looking to the future, various next steps can be taken to further the results 
observed in these experiments.  The first could be to see how the four analogs of interest 
actually do when it comes to killing T. vaginalis.  From our data, it was made evident that 
the drugs are effective at targeting the two major TrxR isoforms, but it still is yet to be 
determined how effective these drugs are at killing the actual organism, critical 
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information needed if these analogs are to be considered serious drug options for 
treatment.   
The qPCR analysis of the basal mRNA levels can also be greatly expanded.  Our 
collaborators lab did similar tests on a different lab strain of T. vaginalis.  Their data 
showed that for their strain, while isoforms 474 and 125 were still expressed at the 
highest levels, isoform 348 had much higher basal levels than strain G3.  Considering that 
we were both looking at lab strains, and there are various clinical strains that we aren’t 
working with, it would be prudent to attempt to characterize basal mRNA levels of all 
known T. vaginalis strains, both lab and clinical.  Perhaps all strains show the same 
pattern of expression as G3, with 474 being expressed at the highest amounts, followed 
next by 125, and then by the other three.  And like observed by our collaborators, some 
differences might exist in actual expression levels, but the trend remains observed.  Or it 
could be that some strains express the isoforms at completely different levels.  
Regardless, knowing would be useful when planning treatment for future patients.  
The mass spectrometry analysis will also need to be conducted.  Human error was 
very likely the cause of the inconsistent results seen for the higher concentration 
treatment of auranofin, and so those tests need to be redone to get a better understanding 
of how exposure to high levels of drug is affecting isoform levels.   
And then of course, future studies can even attempt to focus on possible resistance 
to auranofin.  A resistant cell line can be generated, and mass spectrometry analysis can 
be performed to examine what has changed between susceptible and resistant cells.  
Getting ahead of resistance might allow drugs to be generated that are able to kill 
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resistant cells before these cells even pop up, ensuring that no patients would need to go 
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